Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irpagratinib + atezolizumab
- Development stage
- Unknown
- Lead developer
- Abbisko Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Irpagratinib + atezolizumab** is a combination therapy under clinical development for the treatment of advanced hepatocellular carcinoma (HCC), especially in patients with *FGF19* overexpression. Irpagratinib (ABSK-011) is a highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), developed to target tumors driven by aberrant FGF19-FGFR4 pathway signaling. Atezolizumab is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to enhance antitumor immune responses. This combination leverages both targeted pathway inhibition and immunomodulation, showing promising efficacy, including a reported objective response rate (ORR) of 50% in certain clinical trial cohorts, and a favorable safety profile. The combination is currently under investigation primarily by Abbisko Therapeutics, with atezolizumab manufactured by Roche/F. Hoffmann-La Roche[1][2][3][4].
- Brand names
- Tecentriq
- Other names
- irpagratinib + atezolizumabABSK-011 + atezolizumab
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on irpagratinib + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irpagratinib + atezolizumab.